share_log

Analyzing Apyx Medical (NASDAQ:APYX) & EnVVeno Medical (NASDAQ:NVNO)

Analyzing Apyx Medical (NASDAQ:APYX) & EnVVeno Medical (NASDAQ:NVNO)

分析阿比斯醫療 (NASDAQ: APYX) & 環保醫療 (NASDAQ: NVNO)
Defense World ·  2023/01/14 01:51

enVVeno Medical (NASDAQ:NVNO – Get Rating) and Apyx Medical (NASDAQ:APYX – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations and institutional ownership.

維諾醫療(納斯達克:NVNO-GET評級)和阿皮克斯醫療(納斯達克:APYX-GET評級)都是小盤醫療公司,但哪種投資更好?我們將根據兩家公司的風險、股息、收益、盈利能力、估值、分析師推薦和機構持股的強弱對它們進行比較。

Profitability

盈利能力

This table compares enVVeno Medical and Apyx Medical's net margins, return on equity and return on assets.

此表比較了enVVeno Medical和Apyx Medical的淨利潤率、股本回報率和資產回報率。

Get
到達
enVVeno Medical
EnVVeno醫療
alerts:
警報:
Net Margins Return on Equity Return on Assets
enVVeno Medical N/A -56.38% -53.02%
Apyx Medical -39.28% -39.82% -31.06%
淨利潤率 股本回報率 資產回報率
EnVVeno醫療 不適用 -56.38% -53.02%
阿皮克斯醫療 -39.28% -39.82% -31.06%

Insider and Institutional Ownership

內部人與機構持股

23.1% of enVVeno Medical shares are owned by institutional investors. Comparatively, 65.6% of Apyx Medical shares are owned by institutional investors. 16.3% of enVVeno Medical shares are owned by insiders. Comparatively, 11.6% of Apyx Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

EnVVeno醫療公司23.1%的股份由機構投資者持有。相比之下,Apyx Medical 65.6%的股份由機構投資者持有。EnVVeno Medical 16.3%的股份由內部人士持有。相比之下,Apyx Medical 11.6%的股份由內部人士持有。強大的機構持股表明,對衝基金、捐贈基金和大型基金管理公司相信,一家公司的長期表現將好於大盤。

Earnings & Valuation

收益與估值

This table compares enVVeno Medical and Apyx Medical's top-line revenue, earnings per share and valuation.
此表比較了enVVeno Medical和Apyx Medical的營收、每股收益和估值。
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
enVVeno Medical N/A N/A -$16.53 million ($2.58) -1.83
Apyx Medical $48.52 million 1.85 -$15.17 million ($0.56) -4.62
總收入 價格/銷售額比 淨收入 每股收益 市盈率
EnVVeno醫療 不適用 不適用 -1,653萬美元 ($2.58) -1.83
阿皮克斯醫療 4,852萬美元 1.85 -1,517萬元 ($0.56) -4.62

Apyx Medical has higher revenue and earnings than enVVeno Medical. Apyx Medical is trading at a lower price-to-earnings ratio than enVVeno Medical, indicating that it is currently the more affordable of the two stocks.

Apyx Medical的收入和收益高於enVVeno Medical。Apyx Medical的市盈率低於enVVeno Medical,表明它目前是兩隻股票中更負擔得起的一隻。

Analyst Ratings

分析師評級

This is a breakdown of recent ratings and target prices for enVVeno Medical and Apyx Medical, as provided by MarketBeat.com.

這是由MarketBeat.com提供的enVVeno Medical和Apyx Medical最近的評級和目標價格細目。

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
enVVeno Medical 0 0 0 0 N/A
Apyx Medical 0 1 3 0 2.75
銷售評級 保持評級 購買評級 強勁的買入評級 評級分數
EnVVeno醫療 0 0 0 0 不適用
阿皮克斯醫療 0 1 3 0 2.75

Apyx Medical has a consensus price target of $6.00, suggesting a potential upside of 131.66%. Given Apyx Medical's higher probable upside, analysts plainly believe Apyx Medical is more favorable than enVVeno Medical.

Apyx Medical的普遍目標價為6美元,暗示潛在上漲131.66%。考慮到Apyx Medical更有可能的上行空間,分析師們顯然認為Apyx Medical比enVVeno Medical更有利。

Volatility and Risk

波動性和風險

enVVeno Medical has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500. Comparatively, Apyx Medical has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500.

EnVVeno Medical的貝塔係數為1.27,這表明其股價的波動性比標準普爾500指數高27%。相比之下,Apyx Medical的貝塔係數為1.2,這表明其股價的波動性比標準普爾500指數高20%。

Summary

摘要

Apyx Medical beats enVVeno Medical on 8 of the 12 factors compared between the two stocks.

在兩隻股票比較的12個因素中,Apyx Medical在8個方面擊敗了enVVeno Medical。

About enVVeno Medical

關於enVVeno醫療公司

(Get Rating)

(獲取評級)

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial.

恩維諾醫療公司(納斯達克代碼:NVNO)是一家醫療設備公司,專注於開發創新的生物假體(基於組織的)設備,以提高靜脈疾病治療的護理標準。該公司的主導產品VenoValve是一種一流的外科植入物,正在開發用於治療嚴重的深靜脈慢性靜脈功能不全(CVI)。當腿部深靜脈內的瓣膜受損,導致返回心臟的血液不足時,就會發生深靜脈CVI。出現故障的靜脈瓣膜導致血液向後流動(迴流),並在小腿上積聚,增加腿部靜脈內的壓力(靜脈性高血壓)。在最嚴重的情況下,CVI可導致靜脈潰瘍(開放性皮膚潰瘍),成為慢性且難以治癒。靜脈瓣膜被植入股靜脈,作為替代靜脈瓣膜,旨在減少返流和靜脈高血壓,並恢復正確的定向血液迴流到心臟。據估計,美國約有240萬人受到嚴重的深靜脈CVI影響,他們沒有有效的治療選擇,VenoValve已獲得美國食品和藥物管理局指定的突破設備,目前正在SAVVE美國臨牀試驗中進行評估。

About Apyx Medical

關於阿皮克斯醫療公司

(Get Rating)

(獲取評級)

Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and J-Plasma branded products for the hospital surgical market. It also develops, manufactures, and sells disposable hand pieces, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.

Apyx醫療公司是一家能源技術公司,在全球整容和外科市場開發、製造和銷售醫療設備。該公司分兩個部門運營,先進能源和原始設備製造(OEM)。它提供氦等離子體發生器,用於傳輸射頻能量和氦,以在開放和腹腔鏡手術過程中切割、凝固和消融軟組織。該公司為整形外科市場提供Renuvion品牌的產品,使整形外科醫生、筋膜整形外科醫生和整容內科醫生能夠為組織提供受控的熱,以實現他們預期的結果;以及為醫院外科市場提供J-等離子品牌的產品。它還開發、製造和銷售一次性手機,以及OEM發電機和配件。該公司前身為博維醫療公司,並於2019年1月更名為阿皮克斯醫療公司。阿皮克斯醫療公司成立於1982年,總部設在佛羅裏達州克利爾沃特。

Receive News & Ratings for enVVeno Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enVVeno Medical and related companies with MarketBeat.com's FREE daily email newsletter.

接受enVVeno醫學日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對enVVeno Medical和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論